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Modulation of Serum Anti-thyroglobulin and 
Anti-thyroid Microsomal Autoantibody Levels 
by Levamisole in Patients With Oral Lichen Planus
Hung-Pin Lin,1 Yi-Ping Wang,1,2,3 Jean-San Chia,1,2,3,4 Andy Sun2,3*
Background/Purpose: Several types of serum autoantibodies including anti-thyroglobulin (TGA) and
anti-thyroid microsomal autoantibody (TMA) were detected in patients with oral lichen planus (OLP).
This study evaluated whether Chinese OLP patients had significantly higher frequencies of serum TGA and
TMA than healthy control subjects, and whether levamisole treatment could modulate serum TGA and TMA
levels in Chinese OLP patients.
Methods: This study used a semi-quantitative microtiter particle agglutination test to measure the baseline
serum levels of TGA and TMA in a group of 278 Chinese OLP patients and 53 healthy control subjects.
Forty-one TGA-positive and 48 TMA-positive OLP patients were treated with levamisole for a complete 
period of 1 year, and their serum TGA and TMA levels were measured after treatment.
Results: We found that the frequencies of serum TGA and TMA in patients with OLP (21.6% and 24.5%, respec-
tively), erosive OLP (21.8% and 24.5%, respectively), or non-erosive OLP (19.0% and 23.8%, respectively) were
significantly higher than those (1.9% and 1.9%, respectively) in healthy control subjects. After 1 year of levam-
isole treatment, the serum TGA and TMA titers decreased partially or became undetectable in 36 (88%) TGA-
positive and 46 (96%) TMA-positive OLP patients. At least 9 months or 3 months of levamisole treatment were
needed to reduce the mean serum TGA or TMA titer to a significantly lower level in OLP patients, respectively.
Conclusion: Significantly higher frequencies of serum TGA and TMA were found in Chinese OLP patients
than in healthy control subjects. After 1 year of levamisole treatment, serum TGA and TMA levels were re-
duced partially or became undetectable in approximately 88% of TGA-positive and 96% of TMA-positive
OLP patients.
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Oral lichen planus (OLP) is a chronic inflamma-
tory oral mucosal disease. A previous study has
shown involvement of antigen-specific and non-
specific mechanisms in OLP. Antigen-specific
mechanisms include antigen presentation by basal
keratinocytes and keratinocyte killing by CD8+
cytotoxic T lymphocytes. Nonspecific mecha-
nisms include mast-cell degranulation and matrix
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metalloproteinase activation in OLP lesions.1
Through mast cell/T-cell interactions in OLP le-
sions, mast-cell-released cytokines, chemokines
and matrix metalloproteinases can promote T-cell
activation, migration, proliferation and differen-
tiation.2 OLP is histologically characterized by
liquefaction degeneration of basal epithelial cells
and an intraepithelial and subepithelial infiltrate
of mononuclear cells that are predominantly CD8+.
CD4+ cells are observed mainly in the deep lam-
ina propria.3 An increase in histocompatibility
leukocyte antigen (HLA)-DR-positive CD3+ cells
in the local lesional tissues and peripheral lym-
phocytes also indicates T-cell activation in OLP.4,5
The above findings suggest that OLP is a T-cell-
mediated inflammatory disease.
Levamisole is an immunomodulator that can
modulate T-cell-mediated immunity.6–9 Our pre-
vious studies have found that levamisole can also
modulate abnormal serum interleukin (IL)-6, 
IL-8, tumor necrosis factor (TNF)-α, anti-basal cell
antibody (anti-BCA), and anti-nuclear antibody
(ANA) levels to normal in patients with OLP or
erosive OLP (EOLP).6–9
Previous studies have shown the presence of
serum autoantibodies in several different groups of
OLP patients, including epithelial cell antibody,
ANA, smooth muscle antibody (SMA), anti-mito-
chondrial antibody, gastric parietal cell antibody
(GPCA), thyroglobulin antibody (TGA), thyroid
microsomal antibody (TMA), and desmoglein 1
and 3 antibodies.9–15 In this study, we examined
the frequencies of serum TGA and TMA in a group
of 278 Chinese OLP patients and in 53 healthy
control subjects. We tried to establish whether there
were significantly higher frequencies of serum TGA
and TMA in Chinese OLP patients than in healthy
control subjects, and whether levamisole treat-
ment could modulate serum TGA and TMA levels.
Methods
Patients and normal control subjects
The study group consisted of 278 OLP patients
(46 men and 232 women, age range: 21–82 years,
mean: 55.1 years) without LP of other mucosal
or skin surfaces. The normal control group con-
sisted of 53 healthy subjects (8 men and 
45 women, age range: 21–83 years, mean: 54.7
years) without any oral mucosal or systemic dis-
eases. All the patients and control subjects were
seen consecutively, diagnosed, and treated in the
Department of Oral Diagnosis, National Taiwan
University Hospital from July 2004 to June 2006.
OLP patients with areca quid chewing habit, hyper-
tension, and autoimmune diseases such as sys-
temic lupus erythematosus, rheumatoid arthritis,
Sjögren’s syndrome, pemphigus vulgaris, and 
cicatricial pemphigoid were excluded. In addi-
tion, none of them had taken any prescription
medication for at least 3 months before entering
the study. The 278 OLP patients included 257
with EOLP (42 men and 215 women, age range:
21–83 years, mean: 55.3 years) and 21 with non-
erosive OLP (NEOLP) (4 men and 17 women,
age range: 24–83 years, mean: 52.7 years). They
were selected according to the following criteria:
(1) a typical clinical presentation of radiating,
grayish-white Wickham striae, papules and
plaques, separately or in combination (NEOLP),
and erosion or ulceration of the oral mucosa
(EOLP); and (2) biopsy specimens characteristic
of OLP, that is, hyperkeratosis or parakeratosis, a
slightly acanthotic epithelium with liquefaction
degeneration of the basal epithelial cells, a pro-
nounced band-like lymphocytic infiltrate in the
lamina propria, and the absence of epithelial
dysplasia. EOLP was further divided into major
and minor types according to criteria described
previously.6–8
All OLP patients, regardless of their subtypes,
were treated by levamisole at a dose of 50 mg twice
daily in patients with 30–50 kg body weight, or
50 mg three times daily for those with 50–70 kg
body weight, for 3 consecutive days at the begin-
ning of each 2-week interval. Compliance was
monitored by asking the patients to record the
time at which each drug was taken. Before the start
of therapy, clinical data on all cases were recorded
according to a set protocol, and the patients were
examined by the same dentist at each visit.
Thyroid autoantibodies in oral lichen planus
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Patients were monitored once monthly to record
clinical responses after treatment.
Blood samples were withdrawn from the OLP
patients before treatment, and from normal control
subjects. To assess whether the serum TGA or TMA
levels in TGA- or TMA-positive OLP patients could
be reduced after treatment with levamisole, post-
treatment blood samples were serially obtained
every 3 months until the serum TGA or TMA levels
became undetectable. Informed consent was ob-
tained from each patient or control subject before
collection of the blood samples. This study was
reviewed and approved by the Human Investi-
gation Review Committee at National Taiwan
University Hospital.
Determination of serum TGA and 
TMA levels
TGA and TMA titers were measured by a semi-
quantitative microtiter particle agglutination test
using Serodia-AMC kits (Fuji Rebio Inc., Tokyo,
Japan) as described previously.13,15 Serial 2-fold
dilutions of initial 1:20 dilutions of OLP patients’
and control subjects’ sera were reacted with gelatin
particles sensitized with thyroglobulin or thyroid
microsomal antigen, in the wells of a microti-
tration tray at room temperature for 3 hours. The
results were obtained by reading the settling pat-
terns of the colored gelatin particles using a tray
viewer. Serum that contained TGA or TMA reacted
with the thyroglobulin- or thyroid-microsomal-
antigen-sensitized colored gelatin particles to
form a smooth mat of agglutinated particles in
the microtitration tray. Negative reactions were
characterized by a compact button formed by the
settling of the non-agglutinated particles. TGA or
TMA titers ≥ 1:40 were considered positive.
Statistical analysis
The difference in the frequency of each serum
autoantibody was compared between any two
groups by χ2 or Fisher’s exact test, when appro-
priate. The serum levels of TGA or TMA at base-
line and after treatment were compared to each
other using a paired t test. The result was consid-
ered to be significant if the p value was < 0.05.
Results
Eighty-three OLP patients had either TGA or TMA
in their sera. Of these 83 OLP patients, 15 had TGA
only, 23 had TMA only, and 45 had both autoan-
tibodies. The frequencies of serum TGA or TMA
in different groups of OLP patients and 53 healthy
control subjects are shown in Table 1. We found
that the frequencies of serum TGA and TMA in pa-
tients with OLP (21.6% and 24.5%, respectively),
EOLP (21.8% and 24.5%, respectively) or NEOLP
(19.0% and 23.8%, respectively) were significantly
higher than those (1.9% and 1.9%, respectively)
in healthy control subjects (Table 1). In addition,
female OLP patients had a significantly higher
frequency of serum TGA (24.6%, p = 0.012) or
TMA (27.2%, p = 0.031) than male OLP patients.
Moreover, major EOLP patients had a signifi-
cantly higher frequency of serum TGA (33.6%,
p = 0.000) or TMA (35.5%, p = 0.000) than minor
EOLP patients.
Forty-one TGA-positive (30 were also TMA-
positive) and 48 TMA-positive (30 were also
TGA-positive) OLP patients were treated with
levamisole for a complete period of 1 year, 
and were included for analysis of serum TGA or
TMA changes after levamisole treatment. We found
that, after 1 year levamisole treatment, serum
TGA and TMA could be reduced partially or be-
came undetectable in 36 (88%) TGA-positive and
46 (96%) TMA-positive OLP patients (Table 2).
When the serum TGA and TMA titers in OLP 
patients were checked every 3 months and com-
pared before and after treatment, we found that
the mean serum TGA titer could be reduced to a
significantly lower level after treatment with le-
vamisole for ≥ 9 months. By contrast, 3 months
of levamisole treatment was long enough to re-
duce the mean serum TMA titer to a significantly
lower level in OLP patients compared to the
baseline serum level (Table 3). Patients with a
significant reduction in serum TGA or TMA level
after levamisole treatment also had significant
improvement in signs and symptoms of OLP,
such as a reduction in lesion size and pain
caused by the lesion, healing of the erosive or 
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ulcerative lesion, and transformation of EOLP
into NEOLP.
Discussion
This study showed the presence of serum TGA and
TMA in 21.6% and 24.5% of OLP patients, re-
spectively. These data were comparable to the re-
sults of our previous study (21.3% for TGA and
24.4% for TMA).15 In the present study, we treated
OLP patients with levamisole and found that in
88% of TGA-positive and 96% of TMA-positive
patients, serum TGA and TMA levels were reduced
partially or became undetectable after 1 year of
treatment. The serum TMA titer responded more
sensitively to levamisole treatment than did the
serum TGA titer, because the mean serum TMA titer
was decreased more significantly after 3 months
of treatment than the mean serum TGA titer after
9 months of treatment. Our previous studies have
shown the disappearance of serum anti-BCA in
three of six anti-BCA-positive EOLP patients, and
the disappearance of serum ANA in three ANA-
positive EOLP patients after levamisole treatment.9
In addition, treatment with levamisole for 0.5–7.5
Table 2. Clinical outcomes of 41 thyroglobulin-antibody-positive and 48 thyroid-microsomal-antibody-
positive patients with oral lichen planus after treatment with levamisole for 3, 6, 9 and 12 monthsa
OLP patients
Treatment Duration of levamisole treatment
response 3 mo patient 6 mo patient 9 mo patient 12 mo patient
TGA-positive (n = 41) Partial responseb 20 (49) 20 (49) 20 (49) 20 (49)
Complete responsec 5 (12) 14 (34) 16 (39) 16 (39)
Total 25 (61) 34 (83) 36 (88) 36 (88)
TMA-positive (n = 48) Partial responseb 25 (52) 32 (67) 29 (61) 32 (67)
Complete responsec 5 (11) 8 (16) 13 (27) 14 (29)
Total 30 (63) 40 (83) 42 (88) 46 (96)
aData are presented as n (%). bpartial response: partial reduction of serum TGA or TMA level after levamisole treatment; ccomplete response:
reduction of serum TGA or TMA to an undetectable level after levamisole treatment. OLP=oral lichen planus; TGA= thyroglobulin anti-
body; TMA = thyroid microsomal antibody.
Table 1. Frequencies of serum thyroglobulin and thyroid microsomal antibodies in different groups of oral
lichen planus patients and 53 healthy control subjects
Autoantibodies [positive patient number (%)]
TGA p TMA p
OLP (n = 278) 60 (21.6) 0.001a 68 (24.5) 0.000a
EOLP (n = 257) 56 (21.8) 0.001a 63 (24.5) 0.000a
NEOLP (n = 21) 4 (19.0) 0.021a 5 (23.8) 0.006a
Sex
Female (n = 232) 57 (24.6) 0.012b 63 (27.2) 0.031b
Male (n = 46) 3 (6.5) 5 (10.9)
EOLP
Major type (n = 107) 36 (33.6) 0.000c 38 (35.5) 0.000c
Minor type (n = 150) 20 (13.3) 25 (16.7)
Healthy controls (n = 53) 1 (1.9) 1 (1.9)
aComparison between healthy control and OLP, EOLP or NEOLP groups by χ2 or Fisher’s exact test, when appropriate; bcomparison
between female and male OLP patients by Fisher’s exact test; ccomparison between major and minor EOLP patients by χ2 test.
TGA = thyroglobulin antibody; TMA = thyroid microsomal antibody; OLP = oral lichen planus; EOLP = erosive oral lichen planus;
NEOLP = non-erosive oral lichen planus.
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months can significantly reduce the abnormally
high serum IL-6, IL-8 and TNF-α levels to normal
in patients with OLP or EOLP.7,8 The most impor-
tant feature is that the reduction of autoantibody
or cytokine level after levamisole treatment is 
always accompanied by significant improvement
of signs and symptoms in OLP patients.6–9 These
findings suggest that levamisole treatment returns
abnormal serum autoantibody and cytokine levels
to normal in OLP patients, and is an effective treat-
ment modality for OLP.
Previous studies have demonstrated an overall
incidence of 27–82% for the presence of serum
autoantibodies in several different groups of OLP
or EOLP patients.9–15 Lin et al10 have shown the
presence of serum anti-BCA in 54% (34/63) of
OLP patients. Lundstrom11 has demonstrated the
presence of serum autoantibodies including rheu-
matoid factor, ANA and SMA in 27% of 30 OLP
patients and in 9% of 23 control subjects. Lodi 
et al12 have observed the presence of circulating
antibodies to epithelial antigen in 57% of 14
hepatitis C virus antibody (HCVA)-positive OLP
patients but in none of the 14 HCVA-negative pa-
tients. Carrozzo et al13 have discovered the pres-
ence of serum autoantibodies, including ANA,
SMA, anti-mitochondrial antibody, GPCA and
anti-thyroid antibody in 11 (41%) of 27 HCVA-
positive OLP patients and in 12 (52%) of 23
HCVA-negative patients. Lukac et al14 have dem-
onstrated significantly higher concentrations of
circulating autoantibodies to desmogleins 1 and
3 in 32 EOLP patients than in 50 healthy con-
trols, or in 25 patients with reticular OLP, by 
enzyme-linked immunosorbent assay. Indirect
immunofluorescence also has revealed signifi-
cantly higher frequencies of both desmoglein au-
toantibodies in EOLP patients (82%, 18/22) than
in healthy controls (5%, 1/20), or in patients with
reticular OLP (20%, 3/15). Our recent study has
shown an overall incidence of 60.9% for the pres-
ence of serum autoantibodies in a large group of
320 OLP patients, and significantly higher fre-
quencies of serum ANA, GPCA, TGA and TMA in
OLP patients than in healthy control subjects.15
The above findings suggest that there are signif-
icantly higher frequencies of serum autoanti-
bodies in OLP patients than in healthy control
subjects.
The mechanisms for the induction and produc-
tion of TGA and TMA in the sera of OLP patients
are still not clear. TGA/TMA-positive OLP pa-
tients may also have underlying autoimmune
thyroid diseases that can cause the destruction of
thyroid tissues and result in the release of thyro-
globulin and microsomal autoantigens in the local
thyroid tissues and blood circulation. These au-
toantigens may be phagocytosed and processed
by macrophages and B cells, and presented to the
helper/inducer T cells in OLP patients’ thyroid
tissues, regional lymph nodes, and blood circula-
tion. With the help of T cells, the antigen-specific,
Table 3. Serum autoantibody titers of 41 thyroglobulin-antibody-positive and 48 thyroid-microsomal-
antibody-positive patients with oral lichen planus at baseline and after treatment with levamisole 
for 3, 6, 9 and 12 months
OLP patients
Serum autoantibody Duration of levamisole treatment
titer At baseline 3 mo 6 mo 9 mo 12 mo
TGA-positive Range 40–40,960a 0–40,960 0–20,480 0–10,240 0–5,120
(n = 41) Mean ± SEM 3148 ± 1462 2557 ± 1206 1361 ± 609 712 ± 352 381 ± 175
pb 0.217 0.051 0.033 0.036
TMA-positive Range 40–40,960 0–20,480 0–10,240 0–10,240 0–10,240
(n = 48) Mean ± SEM 4872 ± 1475 2551 ± 623 1509 ± 363 1208 ± 328 1042 ± 326
pb 0.025 0.008 0.004 0.004
aData are presented as the fold of dilution of serum; bcomparison of serum autoantibody titer at baseline and after 3, 6, 9 or 12 months
of levamisole treatment by paired t test. OLP = oral lichen planus; TGA = thyroglobulin antibody; SEM = standard error of the mean;
TMA = thyroid microsomal antibody.
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activated B cells produce high levels of TGA and
TMA in the local thyroid tissues and blood circu-
lation of OLP patients. The locally produced au-
toantibodies in the interstitial fluid may diffuse
into blood capillaries or be drained into lym-
phatic vessels, and finally reach the blood circula-
tion. The locally secreted TGA and TMA together
with those produced in the blood circulation
eventually give rise to significantly higher levels
of serum TGA and TMA in OLP patients than in
healthy control subjects.
Our previous study has shown significantly
higher frequencies of HLA-DRw9 in Chinese OLP
patients.16 HLA-DRw9 has been found to have an
intimate relationship with autoimmune diseases
such as Graves’ disease and Hashimoto’s thyroid-
itis.17,18 HLA-DRw9 in Chinese patients is even
considered to take the place of HLA-DR3 in Cau-
casians in carrying the genes that predispose to
the development of autoimmune diseases.16,18 The
concomitant presence of OLP and underlying
autoimmune thyroid disease trait in HLA-DRw9-
positive Chinese patients might have contributed
to the presence of serum TGA or TMA in some of
our OLP patients.
In conclusion, there were significantly higher
frequencies of TGA and TMA in Chinese OLP pa-
tients than in healthy control subjects. After 1 year
of levamisole treatment, the serum TGA and TMA
levels were reduced partially or became unde-
tectable in approximately 88% of TGA-positive
and 96% of TMA-positive OLP patients.
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